Summit Global Investments’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.62M | Buy |
26,658
+1,761
| +7% | +$103K | 0.1% | 112 |
|
|
2025
Q4 | $1.34M | Buy |
24,897
+6,964
| +39% | +$335K | 0.08% | 137 |
|
|
2025
Q3 | $809K | Buy |
+17,933
| New | +$838K | 0.05% | 230 |
|
|
2025
Q1 | – | Sell |
-11,680
| Closed | -$661K | – | 449 |
|
|
2024
Q4 | $661K | Sell |
11,680
-15,685
| -57% | -$876K | 0.04% | 298 |
|
|
2024
Q3 | $1.42M | Sell |
27,365
-35,829
| -57% | -$1.68M | 0.09% | 182 |
|
|
2024
Q2 | $2.62M | Buy |
63,194
+33,359
| +112% | +$1.49M | 0.18% | 109 |
|
|
2024
Q1 | $1.62M | Sell |
29,835
-8,205
| -22% | -$418K | 0.12% | 127 |
|
|
2023
Q4 | $1.95M | Sell |
38,040
-133,210
| -78% | -$6.99M | 0.13% | 127 |
|
|
2023
Q3 | $9.94M | Sell |
171,250
-90,096
| -34% | -$5.52M | 0.66% | 34 |
|
|
2023
Q2 | $16.7M | Buy |
261,346
+17,946
| +7% | +$1.2M | 1.11% | 14 |
|
|
2023
Q1 | $16.9M | Buy |
243,400
+6,296
| +3% | +$444K | 1.3% | 12 |
|
|
2022
Q4 | $17.1M | Sell |
237,104
-1,768
| -0.7% | -$133K | 1.44% | 14 |
|
|
2022
Q3 | $17M | Sell |
238,872
-21,063
| -8% | -$1.53M | 1.57% | 10 |
|
|
2022
Q2 | $20M | Sell |
259,935
-13,100
| -5% | -$998K | 1.76% | 5 |
|
|
2022
Q1 | $19.9M | Sell |
273,035
-65,419
| -19% | -$4.39M | 1.47% | 10 |
|
|
2021
Q4 | $21.1M | Buy |
338,454
+304,828
| +907% | +$17.9M | 1.35% | 16 |
|
|
2021
Q3 | $1.99M | Sell |
33,626
-1,189
| -3% | -$78.3K | 0.15% | 126 |
|
|
2021
Q2 | $2.32M | Sell |
34,815
-8,479
| -20% | -$553K | 0.14% | 118 |
|
|
2021
Q1 | $2.73M | Sell |
43,294
-504
| -1% | -$31.4K | 0.18% | 99 |
|
|
2020
Q4 | $2.72M | Buy |
43,798
+2,299
| +6% | +$141K | 0.27% | 80 |
|
|
2020
Q3 | $2.5M | Sell |
41,499
-4,517
| -10% | -$272K | 0.26% | 64 |
|
|
2020
Q2 | $2.71M | Buy |
46,016
+26,075
| +131% | +$1.56M | 0.31% | 56 |
|
|
2020
Q1 | $1.11M | Sell |
19,941
-189,716
| -90% | -$11.6M | 0.16% | 82 |
|
|
2019
Q4 | $13.5M | Sell |
209,657
-105,246
| -33% | -$6.03M | 1.46% | 18 |
|
|
2019
Q3 | $16M | Sell |
314,903
-66,494
| -17% | -$3.13M | 1.86% | 8 |
|
|
2019
Q2 | $17.3M | Buy |
381,397
+142,532
| +60% | +$6.64M | 2.18% | 4 |
|
|
2019
Q1 | $11.4M | Buy |
238,865
+9,965
| +4% | +$496K | 1.45% | 17 |
|
|
2018
Q4 | $11.9M | Buy |
228,900
+208,335
| +1,013% | +$11.2M | 1.84% | 9 |
|
|
2018
Q3 | $1.28M | Sell |
20,565
-10
| -0% | -$593 | 0.17% | 93 |
|
|
2018
Q2 | $1.14M | Buy |
20,575
+12,265
| +148% | +$662K | 0.17% | 94 |
|
|
2018
Q1 | $526K | Buy |
+8,310
| New | +$535K | 0.08% | 222 |
|
Other funds holding BMY
VCM
VPM
Summit Global Investments's BMY Position: Q1 2026 in Review
Summit Global Investments increased its Bristol-Myers Squibb (BMY) stake by 7.1% in Q1 2026, buying an estimated $103K and bringing the position to 26,658 shares worth $1.62M. The position accounts for 0.1% of the portfolio, ranked #112.
Summit Global Investments first reported a position in BMY in Q1 2018 and has held it in 31 quarters since. The position peaked at $21.1M in Q4 2021. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Summit Global Investments held 26,658 shares of Bristol-Myers Squibb worth $1.62M as of Q1 2026.
- Summit Global Investments bought 1,761 Bristol-Myers Squibb shares in Q1 2026, an estimated $103K.
- Bristol-Myers Squibb made up 0.1% of Summit Global Investments's portfolio in Q1 2026, its #112 holding.
- Summit Global Investments first reported a position in Bristol-Myers Squibb in Q1 2018 and has held it in 31 quarters since.
- Summit Global Investments's Bristol-Myers Squibb position peaked at $21.1M in Q4 2021.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Summit Global Investments's 13F filing for Q1 2026, filed 7 May 2026.